Ensign Peak Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ensign Peak Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-71,355	Closed	-$3.11M	–	1774
2023 Q3	$3.11M	Buy	71,355 +52,215	+273%	+$1.86M	0.01%	702
2023 Q2	$692K	Buy	19,140 +3,150	+20%	+$130K	﹤0.01%	1508
2023 Q1	$595K	Hold	15,990	–	–	﹤0.01%	1589
2022 Q4	$725K	Sell	15,990 -76,627	-83%	-$4.96M	﹤0.01%	1427
2022 Q3	$6.47M	Hold	92,617	–	–	0.02%	464
2022 Q2	$6.22M	Hold	92,617	–	–	0.01%	481
2022 Q1	$7.62M	Buy	92,617 +727	+0.8%	+$74.3K	0.02%	485
2021 Q4	$13.5M	Buy	91,890 +14,183	+18%	+$2.2M	0.03%	400
2021 Q3	$13.7M	Buy	77,707 +28,835	+59%	+$4.64M	0.03%	372
2021 Q2	$7.89M	Buy	48,872 +22,135	+83%	+$3.55M	0.02%	493
2021 Q1	$4.58M	Buy	26,737 +6,663	+33%	+$1.32M	0.01%	663
2020 Q4	$4.41M	Sell	20,074 -11,034	-35%	-$2.39M	0.01%	657
2020 Q3	$5.17M	Buy	31,108 +7,374	+31%	+$1.01M	0.01%	622
2020 Q2	$2.71M	Sell	23,734 -2,798	-11%	-$271K	0.01%	812
2020 Q1	$2.04M	Buy	26,532 +23,632	+815%	+$2.12M	0.01%	818
2019 Q4	$373K	Buy	+2,900	New	+$280K	﹤0.01%	1554

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Ensign Peak Advisors's MRTX Position: Q4 2023 in Review

Ensign Peak Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 71,355 shares — an estimated $3.11M sold.

Ensign Peak Advisors first reported a position in MRTX in Q4 2019 and held it in 16 quarters. The position peaked at $13.7M in Q3 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Ensign Peak Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Ensign Peak Advisors sold 71,355 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3.11M.
Ensign Peak Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 16 quarters.
Ensign Peak Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $13.7M in Q3 2021.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Ensign Peak Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.